Sotera Health

Executive Summary

Sotera Health is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry. Operating through three core businesses—Sterigenics (sterilization services), Nordion (Cobalt-60 supply), and Nelson Labs (lab testing)—the company plays an essential role in ensuring the safety and efficacy of medical devices, pharmaceuticals, and food products. Despite being privately held, Sotera Health has significant market influence due to its dominant position in ethylene oxide (EO) sterilization, which processes roughly 50% of all sterile medical devices in the U.S. The company's financial performance is strong, with consistent revenue growth driven by increasing demand for sterilization services, particularly in the wake of heightened regulatory scrutiny on infection control. However, the company faces ongoing legal challenges related to historical EO emissions, which have led to significant litigation costs and regulatory uncertainty. Management has been proactive in upgrading emissions controls and engaging with regulators, but the path to full resolution remains uncertain. Overall, Sotera Health is well-positioned in a critical niche, with robust demand tailwinds and a diversified service portfolio that mitigates risks.

Upcoming Catalysts (preview)

• 2026EPA Final Rule on Ethylene Oxide Emissions80% success
• 2026-2027Resolution of Major Litigation Cases60% success
• 2027Capacity Expansion at Key Sterilization Facilities90% success